FGF-21 is an indicator of metabolic syndrome and endocrine dysfunction [46] and BPA binding affinity to FGF-21 may be a novel mechanism of action of BPA in disrupting metabolic regulations leading to metabolic derangement in the body. This evidence concerns the gene FGF21 and metabolic syndrome.